Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary adenosine for prevention of no-reflow in acute myocardial infarction
IRCT20190112042329N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Mar 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of adenosine in myocardial infarction (MI) (3 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Major adverse cardiovascular events during admission, Left ventricular ejection fraction and 2 more. Started Mar 2019; status: completed.
02
Drugs
adenosine
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on IRCT20190112042329N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190112042329N1.